WO2004112730A3 - Method and compositions for treating tumors - Google Patents

Method and compositions for treating tumors Download PDF

Info

Publication number
WO2004112730A3
WO2004112730A3 PCT/US2004/019999 US2004019999W WO2004112730A3 WO 2004112730 A3 WO2004112730 A3 WO 2004112730A3 US 2004019999 W US2004019999 W US 2004019999W WO 2004112730 A3 WO2004112730 A3 WO 2004112730A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
levels
nucleoside analogs
tezacitabine
prodrugs
Prior art date
Application number
PCT/US2004/019999
Other languages
French (fr)
Other versions
WO2004112730A2 (en
Inventor
Sharon Lea Aukermann
Michelle D Bronson
Wendy Fantl
Barbara Hibner
Original Assignee
Chiron Corp
Sharon Lea Aukermann
Michelle D Bronson
Wendy Fantl
Barbara Hibner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Sharon Lea Aukermann, Michelle D Bronson, Wendy Fantl, Barbara Hibner filed Critical Chiron Corp
Publication of WO2004112730A2 publication Critical patent/WO2004112730A2/en
Publication of WO2004112730A3 publication Critical patent/WO2004112730A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Tezacitabine, either alone or in combination with one or more nucleoside analogs or prodrugs thereof, can be use to treat nucleoside analog-resistant tumor, particularly gemcitabine-resistant tumors. Screening tumor samples for ras mutations or screening tumor or other patient samples for levels of cytidine deaminase activity or expression, for levels of thymidine phosphorylase activity, or for levels of thymidylate synthase activity or expression are useful for assessing whether a tumor of a patient is likely to respond to treatment with various nucleoside analogs, particularly tezacitabine, gemcitabine, and combinations of nucleoside analogs or prodrugs thereof.
PCT/US2004/019999 2003-06-18 2004-06-18 Method and compositions for treating tumors WO2004112730A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47915503P 2003-06-18 2003-06-18
US60/479,155 2003-06-18
US48287403P 2003-06-27 2003-06-27
US60/482,874 2003-06-27
US51767503P 2003-11-06 2003-11-06
US60/517,675 2003-11-06

Publications (2)

Publication Number Publication Date
WO2004112730A2 WO2004112730A2 (en) 2004-12-29
WO2004112730A3 true WO2004112730A3 (en) 2005-03-10

Family

ID=33545335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/019999 WO2004112730A2 (en) 2003-06-18 2004-06-18 Method and compositions for treating tumors

Country Status (1)

Country Link
WO (1) WO2004112730A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021551A1 (en) * 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
EP2348131A1 (en) * 2010-01-22 2011-07-27 Institut Curie Low levels of cytidine deaminase as a marker for genetic predisposition to develop cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0843019A2 (en) * 1996-11-08 1998-05-20 Kyowa Medex Co., Ltd. Method for determination of specific nucleic acid sequence, and a reagent therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0843019A2 (en) * 1996-11-08 1998-05-20 Kyowa Medex Co., Ltd. Method for determination of specific nucleic acid sequence, and a reagent therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EDA H. ET AL.: "The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase", CANCER RESEARCH, vol. 58, 15 March 1998 (1998-03-15), pages 1165 - 1169, XP008042567 *
ELLEDGE R.M. ET AL.: "Evaluation of thymidilate synthase RNA expression by polymerase chain reaction", MOLECULAR AND CELLULAR PROBES, vol. 8, 1994, pages 67 - 72, XP002983414 *
RODRIGUEZ G.I.: "Phase I clinical trials of tezacitabine [(E)-2'deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors", CLINICAL CANCER RESEARCH, vol. 8, September 2002 (2002-09-01), pages 2828 - 2834, XP002983415 *

Also Published As

Publication number Publication date
WO2004112730A2 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
Fardi et al. Epigenetic mechanisms as a new approach in cancer treatment: An updated review
Leone et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias
Ren et al. DNA hypermethylation as a chemotherapy target
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
ZA200709011B (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
TR201903587T4 (en) Compounds for increasing telomerase activity.
PH12015500485A1 (en) Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer
NO20053993L (en) Chemical connections.
TW200612918A (en) Lonidamine analogs
Pui et al. Clofarabine
WO2005017493A3 (en) Biomarkers in cancer
JP2011505336A5 (en)
Switzeny et al. Vitamin and antioxidant rich diet increases MLH1 promoter DNA methylation in DMT2 subjects
HRP20100313T1 (en) Method for determining responsiveness to chk1 inhibitors
Ávila-Arroyo et al. Synergistic effect of trabectedin and olaparib combination regimen in breast cancer cell lines
WO2000051639A3 (en) Treatment of neoplastic diseases by radiation
WO2004112730A3 (en) Method and compositions for treating tumors
EP1949903B8 (en) Selective a2a receptor antagonists for the treatment of auricular fibrillation
WO2008087558A3 (en) Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
WO2005000403A3 (en) Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof
BRPI0416870A (en) synergistically anticancer compositions
DE602004004571D1 (en) Dependence of symptom-free survival of 5-FU treated colorectal cancer patients on the ratio of mRNA expression levels from thymidine phosphorylase and dihydropyrimidine dehydrogenase
WO2009021235A3 (en) Methods and compositions for treating cancer
Azuma et al. Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC)
Tesser-Viscaíno et al. Putative antinociceptive action of nitric oxide in the caudal part of the spinal trigeminal nucleus during chronic carrageenan-induced arthritis in the rat temporomandibular joint

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase